Skip to main content
Article thumbnail
Location of Repository

Novel research translates to clinical cases of schizophrenic and cocaine psychosis

By João V Nunes and Patricia A Broderick

Abstract

Pharmacotherapies for schizophrenic and cocaine psychoses are complex but similar because of similarities in their brain neurochemistry and behavioral outcomes. Their neurochemical neuronal mechanisms of action, as shown in preclinical and clinical studies, involve primarily dopaminergic dysfunction and, secondarily, neuroadaptive effects that seem to involve central serotonergic function. Behavioral outcomes of both disorders include hyperactivity and antipsychotic medications can ameliorate psychotic symptoms. Patients with both disorders often arrive at emergency departments and present floridly psychotic with a predominance of positive symptoms, often prompting physicians to select a typical antipsychotic medication such as haloperidol. While this has become conventional wisdom, we believe that to use an atypical antipsychotic medication, such as risperidone, in the treatment of both psychoses is quite rational for long-term management of both positive and negative symptoms. Also, controlled clinical studies have shown that risperidone, an atypical antipsychotic medication, is successful in the treatment of cocaine dependence and withdrawal (Smelson et al 1997, 2002; Grabowski et al 2000). Furthermore, the availability and effectiveness of long-acting risperidone in injectable form opens new possibilities for the long-term management of both disorders. In this paper, we present data which show that the use of risperidone is plausible for effective pharmacotherapy of schizophrenic and cocaine psychoses

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2655083
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2002). Cannabis and Schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci,
    2. (2002). Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia. Psychiatry Res,
    3. (1993). Cocaine and cocaethylene: microdialysis comparison of brain drug levels and effects on dopamine and serotonin.
    4. (1989). Cocaine increases extracellular dopamine in rat nucleus accumbens and ventral tegmental area as shown by in vivo microdialysis.
    5. (1989). Cocaine therapy: the “reward. cascade” link.
    6. (1911). Dementia Praecox or Group of Schizophrenias”.
    7. (1998). Increased striatal dopamine transmission in schizophrenia: confi rmation in a second cohort.
    8. (1982). Negative symptoms in schizophrenia. Defi nition and reliability.
    9. (1987). The diagnosis of schizophrenia.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.